Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, novembre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Apyx Medical Corp
APYX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.56
-0.095
-3.58%
In chiusura: Nov 17, 4:00 PM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Apyx Medical Financials
Apyx Medical (APYX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.410M Est
Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.410 million estimate.
Benzinga Newsdesk
PRO
Apyx Medical Q3 EPS $(0.04) Beats $(0.09) Estimate, Sales $14.030M Beat $13.290M Estimate
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 20 percent increase over losses of $(0.05) per share from the
Benzinga Newsdesk
PRO
Apyx Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $13.884M Beat $13.175M Estimate
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the
Benzinga Newsdesk
PRO
Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.554M Est
Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.554 million estimate.
Benzinga Newsdesk
PRO
Apyx Medical Raises FY2026 Sales Guidance from $57.500M-$58.500M to $59.000M-$60.000M vs $57.988M Est
Apyx Medical (NASDAQ:APYX) raises FY2026 sales outlook from $57.500 million-$58.500 million to $59.000 million-$60.000 million vs $57.988 million estimate.
Benzinga Newsdesk
PRO
Apyx Medical Q1 EPS $(0.05) Beats $(0.10) Estimate, Sales $12.490M Beat $10.868M Estimate
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 50 percent increase over losses of $(0.10) per share from the same
Benzinga Newsdesk